Horizon Pharma plc to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 22, 2016 07:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Availability of QUINSAIR™ (levofloxacin inhalation solution) in Canada for the Treatment of Specific Lung Infections in Adults with Cystic Fibrosis
December 22, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc to Participate in Investor Conference in December
December 08, 2016 16:10 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich's Ataxia
December 08, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
November 14, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Selected as One of Chicago Tribune's 2016 Top Workplaces
November 11, 2016 09:00 ET
|
Horizon Pharma plc
LAKE FOREST, Ill., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring...
Horizon Pharma plc Announces Third-Quarter 2016 Financial Results
November 07, 2016 07:00 ET
|
Horizon Pharma plc
-- Third-Quarter 2016 GAAP Net Sales of $208.7 Million(1);Non-GAAP Adjusted Net Sales of $273.7 Million ---- Third-Quarter 2016 GAAP Net Loss of $5.9 Million; Adjusted EBITDA of $141.2 Million...
Horizon Pharma plc to Participate in Investor Conferences in November
November 04, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in Canada
November 03, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.
October 25, 2016 08:39 ET
|
Horizon Pharma plc
- Adds Two Rare Disease Medicines and Further Diversifies Company Revenue - ...